Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?
Abbott ABT and DexCom DXCM are key players in the continuous glucose monitoring (CGM) market. Abbott's Q2 2026 CGM sales reached $2B, up 9.5%, with new product innovations. DexCom's Q2 2026 revenue rose 13% YoY to $1.31B. The global CGM market is projected to grow to $41.4B by 2033. DXCM shares rose 19.9% in the past year, while ABT shares fell 11.5%.
How this was made
The 30-second read
Why it matters
While new product approvals and revenue growth are disclosed, the article offers no actionable trade signal, serving mainly as sector insight.
Market read
Both firms are key players in a fast‑growing CGM market, but the article is a comparative overview rather than a catalyst‑driven news event.
What to watch
Potential regulatory hurdles for new indications and competition from emerging low‑cost CGM entrants.
Background
The piece compares Abbott Laboratories (ABT) and DexCom (DXCM) on recent product developments, sales growth, and market outlook in the continuous glucose monitoring space.
Ticker impact
The article discusses Abbott's recent CE Mark approval for Libre Duo and its Q2 2026 CGM sales exceeding $2 billion.
Limited short‑term move; possible modest upside over weeks.
New product approval is a fresh fact, yet the piece is largely comparative and lacks a concrete trade trigger.
The article notes DexCom's 13% YoY revenue rise to $1.31 billion and its rollout of the G7 15‑Day system in the U.S.
Modest upside potential if investors focus on growth metrics.
Fresh quarterly revenue figure is disclosed, yet the article is primarily a comparative analysis.
Market effects
Highlights continued growth in the CGM market, reinforcing bullish outlook for the sector.
U.S. healthcare investors may view both stocks favorably.
Signals expanding global demand for continuous glucose monitoring technologies.
Counterpoint
Both companies face pricing pressure and reimbursement uncertainties that could limit upside.
Key entities
- CompanyAbbott Laboratories
U.S. medical device maker with CGM portfolio.
- CompanyDexCom
U.S. specialist in continuous glucose monitoring devices.
